BERLIN, Jan. 21 /CNW/ - Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700), a firm specializing in radioactive compounds for
the treatment of cancer, has renewed the approval of its drug YTTRIGA
(Yttrium-90 chloride) by the European Commission. Five years ago the
European Medicines Agency EMA approved this drug for the first time and
as a result of the current renewal process the drug has now been
granted an indefinite approval.
YTTRIGA is used as an active component in the preparation of numerous
radiopharmaceuticals for the treatment of liver, intestinal and blood
cancers as well as for neuroendocrine tumours. YTTRIGA is coupled with
a tumour-specific peptide or with an antibody which recognizes cancer
cells and binds to them maximizing the dose of ionizing radiation to
the cancerous cells and minimizing radiation exposure to healthy cells.
Pharmaceutical grade YTTRIGA is produced under cGMP in Eckert &
Ziegler's clean room facility in Braunschweig, from which it is shipped
worldwide to radiopharmacy facilities that use it in radiolabeling
The Eckert & Ziegler Group of Companies has around 540 employees is one
of the world's largest providers of isotope technology for radiotherapy
and nuclear medicine.
The Board of Directors
For further information:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rossle-Str. 10, 13125 Berlin, Phone: +49(0)30-94-10-84-138, Fax -112, e-mail: firstname.lastname@example.org, http://www.ezag.de